- Opinion
- [Reporter’s view] What was gained and lost with COVID R&D
- by Kim, Jin-Gu May 25, 2022 05:47am
- Literally, the companies have played it out to the end. By the companies, this reporter is referring to the developers of COVID-19 treatments and vaccines. Just 2 years ago, the developers had received the investors’ utmost interest. Stock prices soared when news broke out that a company is developing COVID-19 treatments or vaccines. The
- Opinion
- The Minister should be appointed to lead policy continuity
- by Lee, Hye-Kyung May 20, 2022 06:11am
- On the 13th, the Yoon Seok-yeol government announced the appointment of vice ministers, ministries, and commissioners. However, as the head of the Ministry of Food and Drug Safety was excluded from the list of appointments, many talks were exchanged about the background. The most credible argument was that the appointment of the head of th
- Opinion
- [Reporter’s View] New govnt signals expanded PE exemptions
- by Eo, Yun-Ho May 18, 2022 05:52am
- The inauguration of a new government brings hope and anticipation to each and every industry. The same goes for multinational pharmaceutical companies. In the pharmaceutical industry, hopes are rising for the expanded eligibility of the pharmacoeconomic evaluation exemption scheme. Although many agendas remain in need of resolution, suc
- Opinion
- [Reporter’s View] Now is the time for drug reclassification
- by Lee, Tak-Sun May 6, 2022 05:46am
- 10 years have already passed since the heated discussion arose on the drug reclassification and sale of over-the-counter drugs in non-pharmacy venues. As the Korean saying goes, even nature can change in one decade. In that not-so-long but also an epoch of a period in terms of change, many drugs have established safety profiles and await bet
- Opinion
- [Reporter’s View] Use of maintenance and adjuvant therapies
- by Eo, Yun-Ho May 4, 2022 06:03am
- Continuous administration of a drug for ‘prevention.' This is not a new concept. Patients have been taking drugs to ‘manage’ their chronic condition for a long time, and drugs such as anticoagulants exist for the purpose of prevention. This only became an issue after the concept of maintenance and adjuvant therapies were introduced
- Opinion
- [Reporter’s View]Recall the purpose of regulating biologics
- by Apr 27, 2022 06:04am
- The Ministry of Food and Drug Safety visited 3 pharmaceutical distributors on the 21st to prepare a new guideline that reflects voices in the field and the realistic difficulties of the industry in preparing to comply with regulations on the distribution of biological products. The government is resetting the guideline after the revised v
- Opinion
- [Reporter’s View] 1st oral abortion pill approval difficult
- by Lee, Hye-Kyung Apr 21, 2022 06:03am
- A year has passed since the decriminalization of the abortion ban has taken effect. The Korean Health and Medical Workers’ Union distributed a press release on the 11th on ‘ensuring safe abortion of the people 1 year after the decriminalization of abortion in Korea.’ The press release contained the request for marketing authorization o
- Opinion
- [Reporter’s View] Patience is a virtue...for drugs?
- by Eo, Yun-Ho Apr 20, 2022 06:05am
- Price falls when supply increases. The same goes for the pharmaceutical market. Although the government can reduce fiscal spending by inducing competition between pharmaceutical companies, this would lead to a delay in NHI reimbursement listing. As we enter the era of high-priced drugs, the government has been exercising the ‘art of
- Opinion
- [Desk] R&D capabilities and Moonshot
- by Chon, Seung-Hyun Apr 19, 2022 05:52am
- Pfizer CEO Albert Bourla introduced Pfizer's COVID-19 vaccine development process through a recently published book called "Moonshot." Every step from the decision to develop a COVID-19 vaccine to clinical trials, large-scale production, and transportation was close to impossible, and it created a miracle with prepared R&D capabilities and ju
- Opinion
- [Reporter's eyes] Despite Tessentrick's high sales
- by Apr 15, 2022 06:03am
- According to Roche audit report, the company recorded sales of 343.9 billion won and operating losses of 69.6 billion won last year. Sales fell 22.5% year-on-year, and operating losses increased. This is the first drop in sales in 10 years for Roche Korea, which has increased its sales every year. It is the largest deficit in 10 years. Roc
